SuperNova and Concile to develop point-of-care diagnostic test

SuperNova Diagnostics has entered into a commercial partnership with European specialist healthcare distributor Concile to develop the point-of-care diagnostic test for assessing wellness deficiencies.

SuperNova will create and manufacture the point-of-care test product, secure regulatory approvals and co-promote the product in the European market.

SuperNova will retain 100% of marketing rights outside of the EU and has the ability to sub-licence or sell directly.

Concile sells and develops diagnostic products for cardiovascular, oncology, wellness, infectious disease, diabetes, metabolic and esoteric diseases.